NAS:OPNT (USA) Also trade in: Germany

Opiant Pharmaceuticals Inc

$ 13.05 0 (0%)
Volume: 3,065 Avg Vol (1m): 19,597
Market Cap $: 52.14 Mil Enterprise Value $: 28.37 Mil
P/E (TTM): 0.00 P/B: 3.07
Earnings Power Value -665.79
Net Current Asset Value 4.29
Tangible Book 4.29
Projected FCF 1.84
Median P/S Value 16.56
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 10000, Max: 10000
Current: 10000
0.01
10000
Equity-to-Asset 0.64
Equity-to-Asset range over the past 10 years
Min: -18.7, Med: 0.01, Max: 0.86
Current: 0.64
-18.7
0.86
Interest Coverage No Debt
Interest Coverage range over the past 10 years
Min: 1773.25, Med: 10000, Max: 10000
Current: 10000
1773.25
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.97
DISTRESS
GREY
SAFE
Beneish M-Score -3.40
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 3.99%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -77.41
Operating Margin range over the past 10 years
Min: -445.1, Med: -114.87, Max: 38.45
Current: -77.41
-445.1
38.45
Net Margin % -76.71
Net Margin range over the past 10 years
Min: -454.06, Med: -115.27, Max: 35.68
Current: -76.71
-454.06
35.68
ROE % -92.91
ROE range over the past 10 years
Min: -200.02, Med: -200.02, Max: -92.91
Current: -92.91
-200.02
-92.91
ROA % -59.87
ROA range over the past 10 years
Min: -20196.75, Med: -2432.84, Max: 103.72
Current: -59.87
-20196.75
103.72
ROC (Joel Greenblatt) % -9314.54
ROC (Joel Greenblatt) range over the past 10 years
Min: -1412666.67, Med: -221085.71, Max: 141860
Current: -9314.54
-1412666.67
141860
3-Year Total Revenue Growth Rate 108.20
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 76.3
Current: 76.3
0
76.3
3-Year Total EBITDA Growth Rate -44.60
N/A
3-Year EPS w/o NRI Growth Rate -22.30
N/A

» OPNT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:OPNT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:SNSS OSTO:ITECH XKRX:057880 TSXV:ARCH ROCO:6461 ROCO:4186 XTAE:BLRX NAS:ISEE TPE:4133 LSE:FARN NAS:EYEN ASX:MDC ASX:OCC OSTO:SENZA NGM:GTAB B XCNQ:PVOT OTCPK:ARTH AMEX:AMPE NAS:GNCA NAS:NLNK
Traded in other countries 8OP.Germany
Address 201 Santa Monica Boulevard, Suite 500, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The pipeline product of the company candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine.

Ratios

Current vs industry vs history
Forward PE Ratio 29.67
N/A
PB Ratio 3.07
PB Ratio range over the past 10 years
Min: 1.77, Med: 3.49, Max: 1651.3
Current: 3.07
1.77
1651.3
PS Ratio 2.45
PS Ratio range over the past 10 years
Min: 0.74, Med: 3.11, Max: 33.06
Current: 2.45
0.74
33.06
EV-to-EBIT -2.08
EV-to-EBIT range over the past 10 years
Min: -3, Med: -1.4, Max: 34.5
Current: -2.08
-3
34.5
EV-to-EBITDA -2.08
EV-to-EBITDA range over the past 10 years
Min: -3, Med: -1.4, Max: 34.4
Current: -2.08
-3
34.4
EV-to-Revenue 1.63
EV-to-Revenue range over the past 10 years
Min: 0.1, Med: 2.6, Max: 31.2
Current: 1.63
0.1
31.2
Current Ratio 2.77
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
0.01
7.86
Quick Ratio 2.77
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
0.01
7.86
Days Sales Outstanding 40.31
Days Sales Outstanding range over the past 10 years
Min: 11.51, Med: 74.2, Max: 117.19
Current: 40.31
11.51
117.19
Days Payable 35.55
Days Payable range over the past 10 years
Min: 27.18, Med: 27.18, Max: 35.55
Current: 35.55
27.18
35.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.50
3-Year Share Buyback Rate range over the past 10 years
Min: -38.6, Med: -6.4, Max: 22.1
Current: -17.5
-38.6
22.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.04
Price-to-Tangible-Book range over the past 10 years
Min: 2.12, Med: 3.3, Max: 2742.14
Current: 3.04
2.12
2742.14
Price-to-Projected-FCF 7.09
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.74, Med: 5.97, Max: 13.14
Current: 7.09
2.74
13.14
Price-to-Median-PS-Value 0.79
Price-to-Median-PS-Value range over the past 10 years
Min: 0.3, Med: 1.01, Max: 5.98
Current: 0.79
0.3
5.98
Earnings Yield (Joel Greenblatt) % -48.27
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7658.5, Med: -48.6, Max: 533.7
Current: -48.27
-7658.5
533.7

More Statistics

Revenue (TTM) (Mil) $ 17.71
EPS (TTM) $ -4.06
Beta 0.36
Volatility % 65.74
52-Week Range $ 9.98 - 29.55
Shares Outstanding (Mil) 4

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y